Search clinical trials for: minimal residual disease

Total 381952 results

Peter MacCallum Cancer Centre, Australia
AbbVie

Not yet recruiting

MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma (EpLCART)

Relapsed/Refractory Large B-cell Lymphoma

Australia
The First Affiliated Hospital of Soochow University

Not yet recruiting

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

Multiple Myeloma | Newly Diagnosed | MRD | High Risk
Exact Sciences Corporation
Labcorp Corporation of America Holdings, Inc

Recruiting

First CORRECT Study of Minimal Residual Disease (MRD) Detection in Colorectal Cancer (MRD)

Colorectal Cancer

United Kingdom, Spain, Italy, Israel
AbbVie

Recruiting

A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in Japan

Chronic Lymphocytic Leukemia

Japan
M.D. Anderson Cancer Center
Bellicum Pharmaceuticals, Inc.

Not yet recruiting

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

Colorectal Cancer | Minimal Residual Disease

United States
Nantes University Hospital
Janssen Pharmaceutica

Not yet recruiting

Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma (IFm2022-01)

Multiple Myeloma

France
Fudan University

Not yet recruiting

Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)

Lung Cancer | Minimal Residual Disease | EGFR Gene Mutation
Institute of Hematology & Blood Diseases Hospital...

Recruiting

Detecting Minimal Residual Diseases (MRD) and Monitoring Clonal Evolution Using Ultrasensitive Chromosomal Aberrations Detection (UCAD) in Multiple Myeloma

Multiple Myeloma
University Hospital, Montpellier

Not yet recruiting

French Assessment of MRD by Liquid Biopsies in Stage III CRC Patients (FRENCH.MRD.CRC)

Colorectal Cancer | Minimal Residual Disease | Liquid Biopsy | Stage III Colon Cancer
University Hospital, Montpellier

Not yet recruiting

French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM)

Colorectal Cancer | Liver Metastases | Minimal Residual Disease | Liquid Biopsy | Stage IV Colorectal Cancer | ctDNA
University Hospital, Montpellier

Not yet recruiting

French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)

Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Resectable | Minimal Residual Disease | Liquid Biopsy | ctDNA
The First Hospital of Jilin University

Recruiting

Detection of Minimal Residual Disease in Resectable Stage II-IIIB Non-small Cell Lung Cancer

Lung Cancer

China
Gruppo Oncologico del Nord-Ovest

Not yet recruiting

Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease (TRINITY)

Gastric Cancer | HER2-positive Gastric Cancer

Italy
Personalis Inc.

Recruiting

ctDNA Based MRD Testing for NAC Monitoring in TNBC (B-STRONGER-I)

Minimal Residual Disease | TNBC - Triple-Negative Breast Cancer

United States
Jiangsu Cancer Institute & Hospital

Recruiting

MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC

Non-small Cell Lung Cancer

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma

Multiple Myeloma

China
Qilu Hospital of Shandong University
The Affiliated Hospital of Qingdao University; Shandong Provincial Hospital; Jinan... and other collaborators

Recruiting

Minimal Residual Disease-guided Adjuvant Therapy for Gastric Cancer

Stage II-III Gastric Cancer

China
Fudan University
Shanghai Weihe Medical Laboratory Co., Ltd.

Not yet recruiting

Assessment of Early Pancreatic Cancer Prognosis by Minimal Residual Disease Using Multi-omics Approach

Pancreatic Ductal Adenocarcinoma

China
H. Lee Moffitt Cancer Center and Research Institute
Kite, A Gilead Company

Recruiting

Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Acute Lymphoblastic Leukemia | B-Cell Lymphoblastic Leukemia

United States
University of Oklahoma

Not yet recruiting

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

Androgen Deprivation Therapy | Locally Advanced Prostate Cancer

United States
Zhejiang University

Recruiting

Prospective, Single-arm, Multicenter Clinical Study on Haploidentical Hematopoietic Stem Cell Transplantation in Patients With MRD Positive CD19+ALL Treated With Conditioning Regimens Containing Blinatumomab

Acute Lymphoblastic Leukemia

China
University Medical Center Groningen
Centre Hospitalier Universitaire de Nice; LungenClinic Grosshansdorf

Recruiting

Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC (MRD-LUNG)

Lung Cancer Stage III

France, Germany, Netherlands
Claus Lindbjerg Andersen
Karolinska Institutet; Medical University of Graz; University of Aarhus; Universitätsklinikum... and other collaborators

Recruiting

Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Colorectal Cancer

Colorectal Cancer Stage III | Liver Metastasis Colon Cancer

Germany, Denmark, Austria, France, Sweden
FengYan Jin

Not yet recruiting

A Perspective, Single Center Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment (MRD)

Multiple Myeloma | Minimal Residual Disease
Gruppo Italiano Malattie EMatologiche dell'Adulto

Not yet recruiting

Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and Venetoclax

Minimal Residual Disease | AML, Adult
M.D. Anderson Cancer Center

Recruiting

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

Ovarian Cancer

United States
University of Aarhus
Aarhus University Hospital

Recruiting

DANISH.MRD: Danish Assessment of Minimal Residual Disease by Liquid Biopsies (DANISH_MRD)

Colorectal Neoplasms | Colorectal Cancer | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage I

Denmark
Guangdong Provincial People's Hospital
Shenzhen Chipscreen Biosciences Co.Ltd

Recruiting

A Study of Chidamide With AZA in MRD Positive AML After Transplant

Minimal Residual Disease | AML, Adult

China
Institute of Hematology & Blood Diseases Hospital
Hangzhou Qihan Biotech Co.,Ltd.

Not yet recruiting

Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia

Minimal Residual Disease | AML, Adult

China
WeiWei Xiao
Haplox Biotechnology Co., Ltd.

Recruiting

Predicting the Efficacy and Prognosis of Rectal Cancer Patients Based on ctDNA-MRD Technology

Minimal Residual Disease | Circulating Tumor DNA | Rectal Adenocarcinoma | Neoadjuvant Chemoradiotherapy

China
University of Southampton
AstraZeneca; Natera, Inc.

Recruiting

Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer (DECIPHER)

Gastrooesophageal Cancer

United Kingdom
Instituto do Cancer do Estado de São Paulo
Servier

Recruiting

Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil (BRALLA)

Acute Lymphoid Leukemia | Chemotherapeutic Toxicity | Minimal Residual Disease | Gene Abnormality

Brazil
Assistance Publique - Hôpitaux de Paris
CARPEM, Institut du Cancer Paris; Centre de recherche des Cordeliers; METHYS DX

Recruiting

Circulating Tumor DNA Study in Patients With Endometrial Cancer (ctDNA-endo)

Endometrial Cancer

France
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Recruiting

Mini-invasive Detection of Residual Disease in Breast Cancer Patients in Remission After Primary Chemotherapy

Breast Cancer

Italy
Hebei Medical University Fourth Hospital

Recruiting

Minimally Residual of Esophageal Cancer 001 (ECMRD-001)

Esophageal Carcinoma | Minimal Residual Disease

China
Fondazione Italiana Linfomi - ETS
Roche Pharma AG

Recruiting

Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi (FIL_GAZEBO)

Follicular Lymphoma

Italy
Guangdong Provincial People's Hospital
Haplox

Not yet recruiting

Efficacy Evaluation and Recurrence Monitoring of Therapy for Esophageal Squamous Cell Carcinoma Based on ctDNA-MRD.

Esophageal Squamous Cell Carcinoma | Minimal Residual Disease

China
Suzhou Municipal Hospital

Recruiting

Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)

Cervical Cancer

China
The First Hospital of Jilin University

Not yet recruiting

Minimal Residual Disease Dynamic Monitoring in First-Line Serplulimab Plus Chemotherapy in Treatment of Extensive Small Cell Lung Cancer: An Observational Study

Lung Cancer
Peking University People's Hospital

Recruiting

Clinical Research of Drug Holiday Based on MRD Detection in GIST Patients at High Risk of Recurrence

Gastrointestinal Stromal Tumors

China
Xiaojun Xu

Not yet recruiting

Minimal Residual Disease Quantification by Next-generation Sequencing in Pediatric B-ALL Children Patients Treated With Blinatumomab Consolidation

Acute Lymphoblastic Leukemia, Pediatric
Washington University School of Medicine
Karyopharm Therapeutics Inc

Recruiting

Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant

Multiple Myeloma | Myeloma-Associated Amyloidosis

United States
The First Affiliated Hospital with Nanjing Medical...

Recruiting

ctDNA Detection of MRD in Predicting Postoperative Recurrence in Biliary Tract Cancers：A Multicenter Prospective Trial

Biliary Tract Cancer

China
Masonic Cancer Center, University of Minnesota

Recruiting

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Acute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | AML | Acute Leukemia | Neurofibromatosis 1 | Hematologic Malignancy | Myelodysplasia | Minimal Residual Disease | Chromosome Abnormality | Monosomy 7 | Remission | Somatic Mutation | Cytogenetic Abnormality | TP53 | Fetal Hemoglobin | Intrachromosomal Amplification of Chromosome... and other conditions

United States
Medical College of Wisconsin

Recruiting

Elimination of Minimal Residual Disease After Transplant (EMAT)

Multiple Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Pirtobrutinib and Venetoclax Combined With Minimal Residual Disease Detection for Previously Untreated Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
M.D. Anderson Cancer Center

Recruiting

Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas

Lymphoma

United States
National Cancer Institute (NCI)

Recruiting

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung | Non-Small Cell Lung Cancer | Non-Small Cell Lung Carcinoma | Carcinomas

United States
Rajshekhar Chakraborty, MD
Hope Foundation

Recruiting

Non-invasive MRD Assessment in Multiple Myeloma (NIRVANA)

Myeloma

United States
Sun Yat-sen University

Recruiting

Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT (SURPASS)

Limited Stage Small Cell Lung Cancer

China

Search clinical trials for: minimal residual disease

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United States

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations